1. Home
  2. AURA

as 10-08-2025 9:37am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Founded: 2007 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 396.8M IPO Year: 2021
Target Price: $22.29 AVG Volume (30 days): 283.0K
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.95 EPS Growth: N/A
52 Week Low/High: $4.34 - $12.38 Next Earning Date: 11-11-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Stock Insider Trading Activity of Aura Biosciences Inc. (AURA)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Elazzouzi Amy AURA Senior Vice President, Finance Aug 18 '25 Sell $6.70 7,722 $51,737.40 86,558

Share on Social Networks: